Perimetry Research Articles

Efficacy of Topical 0.05% Cyclosporine A for Ocular Surface Disease Related to Topical Anti-Glaucoma Medications.

Purpose: We aimed to determine the therapeutic efficacy of 0.05% topical cyclosporine A (CsA) for chronic ocular surface disease (OSD) in patients using benzalkonium chloride (BAK)-preserved antiglaucoma eye drops. Methods: A prospective, randomized, paired-eye, controlled clinical trial was conducted with participants who had been instilling at least one BAK-preserved topical antiglaucoma drug in both eyes for at least 6 months. Topical CsA was only applied in randomly selected unilateral eyes. Visual field (VF) indices, ocular surface parameters, tear meniscus height (TMH), and matrix metalloproteinase-9 (MMP-9) immunoassay were evaluated at baseline and at 2 and 4 months. Results: Seventy eyes from 35 participants were included in the study. The Schirmer I, tear breakup time, and TMH increased by 4.5 ± 8.6 mm (P < 0.01), 5.0 ± 5.3 s (P < 0.001), and 85.4 ± 159.0 μm (P < 0.01) in the treated eyes at 4 months from baseline, respectively. The ocular staining score and MMP-9 positivity in the treated eyes decreased by 2.2 ± 1.3 (P < 0.001) and 0.7 ± 0.9 points (P < 0.001), respectively, at 4 months. In untreated eyes, only TMH increased by 41.4 ± 92.1 μm (P = 0.016) from baseline to 4 months. In VF indices, the tracking failure frequency was 19.09% ± 21.62%, and the test duration was 336.0 ± 79.5 s in the treated eyes at 4 months, which were lower than 34.37% ± 23.13% (P < 0.001) and 375.9 ± 70.7 s (P < 0.05) in the nontreated eyes. Conclusion: Application of topical 0.05% CsA significantly improved the OSD parameters and the reliability indices of VF tests. This study was registered with the Clinical Research Information Service (CRIS) (number KCT0007124).

P.107 Endocrine and vision outcomes following 90Yttrium therapy for cystic sellar lesions: a prospective cohort study

Background: Due to high risk of recurrence and complications associated with microsurgical resection or aspiration of enlarging cystic sellar lesions, stereotactic intracavitary irradiation with 90Yttrium (90Yt) has been proposed as an alternative to mitigate these challenges. Long-term efficacy data for this procedure is lacking. Methods: We conducted a Health Canada approved, single-centre, prospective cohort study to assess the effect of 90Yt therapy on cyst volume, visual field (VF) testing and endocrine function. All patients underwent right frontal stereotactic insertion of 90Yt colloid (200 Gy cyst wall). Results: 22 patients [mean age = 63.5 (± 15.4) years] received 90Yt therapy. Mean follow-up was 52 (5-113) months. Cysts included: craniopharyngioma (86%), Rathke’s cleft cyst (9%) and cystic prolactinoma (5%). Mean cyst volume reduction was 77% at 12-months (5.2 ± 4.5 cc to 1.2 ± 1.5 cc; p = 0.002). Rate of pre- and post-op hormonal dysfunction was 59% and 68%, respectively (p = 0.50). Pre-operative VF deficits were found in 68% of patients, of which 32% normalized and 36% remained stable (p = 0.180). Worsened vision was detected in 9% of patients post-operatively. Conclusions: 90Yttrium therapy significantly reduces sellar cyst size without having a deleterious effect on vision and endocrine function.

Kinetic Perimetry on Virtual Reality Headset.

We present a portable automatic kinetic perimeter based on a virtual reality (VR) headset device as an innovative and alternative solution for the screening of clinical visual fields. We compared the performances of our solution with a gold standard perimeter, validating the test on healthy subjects. The system is composed of an Oculus Quest 2 VR headset with a clicker for participant response feedback. An Android app was designed in Unity to generate moving stimuli along vectors, following a standard Goldmann kinetic perimetry approach. Sensitivity thresholds are obtained by moving centripetally three different targets (V/4e, IV/1e, III/1e) along 24 or 12 vectors from an area of non-seeing to an area of seeing and then transmitted wirelessly to a PC. A Python real-time algorithm processes the incoming kinetic results and displays the hill of vision in a two-dimensional map (isopter). We involved 21 subjects (5 males and 16 females, age range 22-73 years) for a total of 42 eyes tested with our proposed solution, and results were compared with a Humphrey visual field analyzer to test reproducibility and efficacy. isopters generated with the Oculus headset were in good agreement with those acquired with a commercial device (Pearson's correlation values r > 0.83 for each target). we demonstrate the feasibility of VR kinetic perimetry by comparing performances between our system and a clinically used perimeter in healthy subjects. proposed device leads the way for a portable and more accessible visual field test, overcoming challenges in current kinetic perimetry practices.

Comparison of Visual Field Test Measurements With a Novel Approach on a Wearable Headset to Standard Automated Perimetry.

This study of inter-test comparability of a novel visual field application installed on an augmented-reality portable headset and Humphrey field analyzer Swedish interactive thresholding algorithm (SITA) Standard visual field test demonstrates the excellent correlation of mean deviation (MD) and mean sensitivity (MS). To determine the correlation between visual field testing with novel software on a wearable headset versus standard automated perimetry. Patients with and without visual field defects attributable to glaucoma had visual field testing in one eye of each patient with 2 methods: re:Imagine Strategy (Heru, Inc.) and the Humphrey field analyzer (Carl Zeiss Meditec, Inc.) SITA Standard 24-2 program. Main outcome measures included MS and MD, which were evaluated by linear regression, intraclass correlation coefficient (ICC), and Bland Altman analysis for assessment of the mean difference and limits of agreement. Measurements from 89 eyes of 89 patients (18 normal and 71 glaucomas) were compared with both instruments. Linear regression analysis demonstrated an excellent Pearson correlation coefficient of r = 0.94 for MS and r = 0.95 for MD. ICC analysis demonstrated high levels of concordance (ICC = 0.95, P < 0.001 for MS and ICC = 0.94, P < 0.001 for MD). Bland-Altman analysis determined a small mean difference between the two devices (Heru minus Humphrey) of 1.15 dB for MS and 1.06 dB for MD. The Heru visual field test correlated well with SITA Standard in a population of normal eyes and eyes with glaucoma.

Ophthalmologic Evaluation of Fitness to Drive

The ophthalmologist must know the essential principles of the driving fitness assessment. In the case of applications for a driving license renewal, it must always be clarified before the examination whether the fitness to drive is to be checked in accordance with the special regulation for holders of a driving license issued up to December 31, 1998 (see Annex 6 to § 12 of the FeV under 2.2.3 Special regulations for the old German Road Traffic Licensing Regulations). Within the scope of grandfathering, this continues to be valid only for the so-called old holders. A categorization of the manifold concerns regarding fitness to drive or driving ability in everyday practice makes it easier for the ophthalmologist to make a factually justified decision in individual cases. In particular, a distinction must be made between the medical assessment of subjects as applicants for a driving license (first-time applicants or renewal applicants) according to the German Driving License Ordinance (FeV) and the consultation of patients with chronic eye diseases [duty to inform according to the German Patients' Rights Act (PRG) and the German Civil Code (BGB), German Driving License Ordinance (FeV)]. The German Driving License Ordinance contains precise specifications for standardized testing of visual acuity and visual field as the most important partial functions of the eye. A special feature of the identified performance deficits of the eyes is that compensation by other bodily functions or supplementary technical equipment on the vehicle is not yet possible. The ophthalmologist therefore often has the task and responsibility of balancing the individual desire for mobility, in the case of professional drivers even the preservation of their jobs on the one hand, and the general societal need for safety on the other.

Diagnostic Capability of Isolated-Check Visual Evoked Potential for Early to Moderate Primary Open-Angle Glaucoma.

This study aimed to evaluate the diagnostic capability of isolated-check visual evoked potential (icVEP) for primary open-angle glaucoma (POAG) via comparison with visual field (VF) tests and pattern visual evoked potential (PVEP). This cross-sectional study enrolled 68 subjects, including 33 POAG patients and 35 controls. All subjects underwent a complete ophthalmic examination, including icVEP, PVEP, and VF tests. The diagnostic performance, the area under the receiver operating characteristic curve (AUC), the integrated discrimination index (IDI), and the net reclassification index (NRI) were calculated. The clinical benefits of the three tests were compared via decision curve analysis (DCA) of the signal-to-noise ratio (SNR) from icVEP, the P100 latency and amplitude of 1° and 0.25° checks from the PVEP, pattern standard deviation (PSD), and mean deviation (MD) from the VF test. The SNR, MD and PSD, PVEP P100 latency of 0.25° checks, and P100 amplitude (both 1° and 0.25° checks) showed significant differences between the POAG and control groups (* p < 0.05), except for the P100 latency of 1° checks. Regarding diagnostic ability, the three tests, AUC, IDI, and NRI, showed no significant difference (p > 0.05). The DCA showed that the clinical benefits of icVEP (SNR) were comparable to those of VF (MD and PSD) and better than those of PVEP (P100 latency and amplitude). In addition, no significant difference was found in the consistency analysis of the qualitative comparison between the icVEP, VF, and PVEP (McNemar p > 0.05). In this study, icVEP showed a diagnostic ability for early to moderate POAG patients comparable to VF and PVEP. IcVEP might be applied as a supplementary psychophysical examination method in addition to VF examinations for special POAG populations who have difficulty cooperating with the VF examination.

Optic Nerve Head Changes After Intraocular Pressure-Lowering Glaucoma Surgeries Using Optical Coherence Tomography.

Optic nerve head (ONH) changes were detected with swept-source optical coherence tomography (SS-OCT) after intraocular pressure (IOP)-lowering glaucoma surgeries. The aim of this study was to detect changes in the ONH with SS-OCT after IOP-lowering procedures. Patients with progressing glaucoma who were referred for IOP-lowering procedures were included. The participants underwent a 24-2 visual field test and SS-OCT (DRI OCT Triton Plus; Topcon). IOP and SS-OCT scans were obtained during the preoperative period and up to 7 days and 30-90 days postoperatively. ONH parameters were measured with a B -scan at the center of the optic disc and an average of 5 central B -scans. The hypotenuse of the ONH cup (HOC) was calculated using the Pythagorean theorem: hypotenuse 2 = leg1 2 + leg2 2 , considering the length and depth of the cup as the legs of a right triangle. We also evaluated changes in Bruch membrane opening (BMO)-to-BMO diameter. Statistical analysis was performed using generalized estimating equations. A total of 15 eyes were included. The mean patient age was 70 (SD, 11.04) years. The mean circumpapillary retinal nerve fiber layer was 60.13 (SD, 23.21) µm and the visual field mean deviation was -13.29 (SD, 8.5) dB. The mean IOP at each visit was: 20.5 (SD, 4.99); 11 (SD, 4.95), and 15.7 (SD, 5.04), respectively. The mean HOC, the mean depth and length of the ONH cup, and the BMO-to-BMO diameter decreased significantly after the IOP-lowering procedures. The HOC evaluated with SS-OCT significantly decreased after IOP-lowering surgeries. This parameter was useful for evaluating short-term changes in the ONH.

Practice Patterns of Screening for Hydroxychloroquine Retinopathy in South Korea

Practice patterns of hydroxychloroquine retinopathy screening have not yet been reported at a national level in South Korea. To investigate the practice patterns of timing and modality for hydroxychloroquine retinopathy screening in South Korea. This nationwide population-based cohort study of patients in South Korea used data from the national Health Insurance Review and Assessment database. Patients at risk were identified as those who had initiated hydroxychloroquine therapy between January 1, 2009, and December 31, 2020, and used it for 6 months or more. Patients were excluded if they underwent any of the 4 screening modalities recommended by the American Academy of Ophthalmology (AAO) for other ophthalmic diseases prior to hydroxychloroquine use. The timing and modalities of screening used in baseline and monitoring examinations were assessed between January 1, 2015, and December 31, 2021, among patients at risk and long-term (≥5 years) users. Adherence of baseline screening practices to the 2016 AAO recommendations (fundus examination within 1 year of drug use) was evaluated; adherence of monitoring examinations in year 5 was classified as appropriate (≥2 tests recommended by the AAO), unscreened (no test performed), and underscreened (insufficient number of tests). Timing of screening and modalities used at baseline and monitoring examinations. A total of 65 406 patients at risk (mean [SD] age, 53.0 [15.5] years; 50 622 women [77.4%]) were included; 29 776 patients were long-term users (mean [SD] age, 50.1 [14.7] years; 24 898 women [83.6%]). Baseline screening was performed for 20.8% of the patients within 1 year, with a gradual increase from 16.6% in 2015 to 25.6% in 2021. Monitoring examinations, mostly using optical coherence tomography and/or visual field tests, were performed for only 13.5% of the long-term users in year 5 and for 31.6% of the long-term users after 5 years. Appropriate monitoring was performed for less than 10% of long-term users each year from 2015 to 2021; however, the percentage gradually increased over time. The percentage of patients undergoing any monitoring examination in year 5 was 2.3 times greater for those who had received baseline screening than for those who did not (27.4% vs 11.9%; P < .001). This study suggests there is an improving trend in retinopathy screening among hydroxychloroquine users in South Korea; however, most long-term users remained unscreened after 5 years of use. Baseline screening may be useful in reducing the number of unscreened long-term users.

Factors Affecting Visual Acuity and Central Visual Function in Glaucoma Patients With Myopia

To investigate associated factors including structural parameters of myopia and vessel density (VD) using optical coherence tomography angiography (OCT-A) to visual acuity (VA) and central visual function in glaucoma patients with myopia. Retrospective cross-sectional study METHODS: Sixty-five eyes of 60 glaucoma patients with myopia and without media opacity and retinal lesions were include. Both Swedish interactive thresholding algorithm (SITA) 24-2 and 10-2 visual field (VF) testing were performed. Superficial and deep VD in the peripapillary and macular regions were evaluated using OCT-A; retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GCIPL) thicknesses were measured. β-zone peripapillary atrophy (PPA) area, disc torsion, disc-fovea distance, and peripapillary choroidal thickness were measured. Decreased VA was defined as best-corrected VA <20/25. The worse mean deviation of SITA 24-2, thinner GCIPL thickness, and lower deep peripapillary VD were associated with the presence of central VF damage in glaucoma patients with myopia. Thinner GCIPL thickness, lower deep peripapillary VD, and longer disc-fovea distance were associated with decreased VA in logistic regression analysis. Thinner GCIPL thickness, lower deep peripapillary VD, and larger β-zone PPA area were associated with lower VA in linear regression analysis. Deep peripapillary VD showed a positive correlation with GCIPL thickness, whereas there was no relationship between deep peripapillary VD and RNFL thickness. Decreased VA in glaucoma patients with myopia was associated with lower deep peripapillary VD and papillomacular bundle damage. Lower deep peripapillary VD was independently associated with decreased VA along with thinner GCIPL thickness. Therefore, this could be stated that decreased VA in glaucoma patients is related to the damage location and the status of blood flow in the optic nerve head.

A pilot clinical study of complex rhegmatogenous retinal detachment treatment via foldable capsular buckle scleral buckling

BackgroundTo evaluate the feasibility of and identify problems in treating complex rhegmatogenous retinal detachment using foldable capsular buckle scleral buckling.MethodsThis prospective clinical study enrolled five patients with complex rhegmatogenous retinal detachment treated with foldable capsular buckle scleral buckling at the 988th Hospital of People’s Liberation Army Joint Logistic Force, China. During the 24-week follow-up period, the patients underwent measurements of their best-corrected visual acuity, slit-lamp examination, indirect ophthalmoscopy, and visual field testing. Additionally, B-ultrasound and fundus photography of the patients’ retinal reattachments helped evaluate the treatment’s post-surgery efficacy. We determined the safety of foldable capsular buckle scleral buckling based on infection, eye pain, diplopia, elevated intraocular pressure, and other postoperative severe complications.ResultsAll five patients’ complex rhegmatogenous retinal detachments were successfully treated and evaluated via B-ultrasound and fundus photography after surgery. Visual acuity was enhanced in four patients 24 weeks after surgery, while the remaining patients developed diplopia after surgery. No other complications were observed.ConclusionThis pilot study preliminarily determined that foldable capsular buckle scleral buckling is feasible for efficient and safe treatment of complex rhegmatogenous retinal detachment. These results support this surgery as a potential and novel alternative to current extraocular procedures for treating complex rhegmatogenous retinal detachment.Trial registrationThe prospective observational clinical study protocol was approved by the Institutional Review Board and Ethics Committee and registered at the clinical research center in the 988th Hospital of People’s Liberation Army Joint Logistic Force, China (9,882,019,000).

A potential primary endpoint for clinical trials in glaucoma neuroprotection

The purpose of this retrospective, longitudinal study is to evaluate the relationship between MD slope from visual field tests collected over a short period of time (2 years) and the current United States’ Food and Drug Administration (FDA) recommended endpoints for visual field outcomes. If this correlation is strong and highly predictive, clinical trials employing MD slopes as primary endpoints could be employed in neuroprotection clinical trials with shorter duration and help expedite the development of novel IOP-independent therapies. Visual field tests of patients with or suspected glaucoma were selected from an academic institution and evaluated based on two functional progression endpoints: (A) five or more locations worsening by at least 7 dB, and (B) at least five test locations based upon the GCP algorithm. A total of 271 (57.6%) and 278 (59.1%) eyes reached Endpoints A and B, respectively during the follow up period. The median (IQR) MD slope of eyes reaching vs. not reaching Endpoint A and B were −1.19 (−2.00 to −0.41) vs. 0.36 (0.00 to 1.00) dB/year and −1.16 (−1.98 to −0.40) vs. 0.41 (0.02 to 1.03) dB/year, respectively (P < 0.001). It was found that eyes experiencing rapid 24-2 visual field MD slopes over a 2-year period were on average tenfold more likely to reach one of the FDA accepted endpoints during or soon after that period.

Abstract #1401779: Rare Case of Functional Gonadotroph Adenoma

Of all pituitary adenomas, approximately 25-35% are clinically nonfunctioning or "silent" and of those approximately 70-90% are gonadotropin adenomas making them the most common nonfunctional pituitary macroadenoma. However, it is important to know that gonadotropin adenomas can be functional and that gonadotropin excess can result in clinical symptoms and lab abnormalities. This case demonstrates an example of a functional gonadotropin pituitary adenoma overproducing FSH resulting in high-normal testosterone level in addition to compressive symptoms of the optic chiasm. 57-year-old African-American male with pre-diabetes mellitus and gout (only home meds are allopurinoL 300 MG once daily and indomethacin 50 MG three times daily) presented for evaluation of vision loss and large sellar mass on MRI. Vision loss first noted January 2022 along with occasional headaches for 3-4 months (no headaches prior). Patient eventually saw a neuro-ophthalmologist for visual field testing demonstrating left field deficits concerning for optic nerve compression. He then underwent orbital MRI which demonstrated a large sellar mass extending into bilateral cavernous sinus and effacing and displacing the optic chiasm. During visit, patient admitted to fatigue, constipation, polyuria, and nocturia. He denied‌ breast tenderness, nipple discharge, weight change, temp intolerance, skin/hair change, palpitations, tremors, increase hand/foot size, teeth spacing change, worse glycemic control, hypertension, joint pain, acne, hirsutism, striae, clotting disorders, fractures, decreased libido, or erectile dysfunction. He had no known allergies. Blood pressure109/83 | Pulse 101 | Ht 5' 10" (1.778 m) | Wt 88.2 kg (194 lb 7.1 oz) | SpO2 97% | BMI 27.90 kg/m2. Physical exam: Visual fields intact to confrontation but with some patchy deficits in the left eye only. No other notable findings. Subsequent labs demonstrated appropriate cortisol 11.8 ng/dL with normal ACTH of 17 pg/mL, normal IGF-1 of 95 ng/mL, normal TSH of 1.6 uIU/mL with normal free T4 of 0.8 ng/dL. However, prolactin was mildly elevated at 36.5 ng/mL (presumably from stalk effect given size of tumor) and FSH was impressively elevated at 70.3 mIU/mL with a normal LH of 6.5 mIU/mL and a high-normal total testosterone level of 890 ng/dL which was highly suggestive an FSH-producing functional gonadotropin adenoma. It is important to realize the efficacy of surgical resection of functional non-prolactinoma pituitary tumors, especially when the optic chiasm is involved. Patient underwent transsphenoidal resection of pituitary adenoma and indeed pathology revealed a gonadotroph adenoma with SF1 and alpha subunit. He reported slightly improved vision in left eye and had some residual occasional headaches. Awaiting post-operative labs but anticipate normalization of prolactin and FSH and a likely decrease in testosterone level. Awaiting post-operative visual field testing to demonstrate objective improvement. These should be available by the time of the conference.

Früherkennung eines Aderhautmelanoms – ein Fallbericht

Purpose. This case report describes the accidental early detection of a small choroidal melanoma during a routine optometric examination. The following is a report of a rare case of choroidal melanoma, in a 58-year-old male Caucasian. He wanted to have glasses for computer work and complained of occasional flickering, when seeing in the morning after getting up. Material and Methods. The following optometric measure- ment methods were used: confrontation visual field test, ex- traocular muscle function test, cover test, retinoscopy (Heine Beta 200 Retinoscope), refraction, slit lamp examination (slit lamp Zeiss SL 120) with evaluation of the anterior eye, evalua- tion of the posterior eye (Heine Beta 200 Ophthalmoscope) and handheld fundus camera (Zeiss Visuscout 100). Results. On fundus examination of the left eye, a light pigmented retinal lesion with orange pigment and retinal eleva- tion was seen temporally on the upper vascular arch. Due to the suspected diagnosis of choroidal melanoma, immediate contact was made with a local ophthalmology practice. This confirmed the suspicion and the patient was referred to the University Eye Clinic in Munich. Conclusion. Uveal melanoma is the most common intraocular malignancy and arises from melanocytes in the iris, ciliary body or choroid. Early diagnosis and local treatment are crucial, as survival correlates with primary tumor size. Approx- imately 50 percent of patients will develop metastatic disease with survival of 6-12 months after metastatic diagnosis. The University Eye Clinic Munich confirmed the diagnosis of choroidal melanoma. A robotic Cyberknife radiosurgery was performed. Keywords Uveal Melanoma, Choroidal Melanoma, Cyberknife Radio-surgery

New insights in the multimodal imaging of retinitis pigmentosa.

Retinitis pigmentosa (RP) is a group of inherited rod-cone dystrophies, noted for a high genotypical and phenotypical heterogeneity.Traditionally, VA, visual field, and electroretinography have been used to assess RP progression. However, visual acuity and visual field tests are essentially subjective and, especially in the late stages of the disease, are unable to confidently reveal minor progression. Therefore, there is a need for novel examination modalities that rely on quantitative, structural measurements. In this regard, several non-invasive imaging techniques have been studied, including spectral-domain optical coherence tomography, optical coherence tomography angiography, and fundus autofluorescence. By correlating surrogate biomarkers with functional measurements of the disease, these techniques may be able to develop reliable outcome meters that can be used to gain a deeper understanding of the underlying causes of the disease and to assess the effectiveness of therapy even before an actual loss of vision occurs.In this review, we will summarize the recent imaging findings and biomarkers that have been identified in RP patients. Our goal is to provide information that can promptly aid in selecting patients for clinical trials and new gene therapies, monitoring the disease progression, and evaluating treatment outcomes.

Ocular Manifestations of Septo-optic Dysplasia

Background: Septo-optic dysplasia (SOD) is a congenital deformity of the brain which can result in neurologic, systemic, and physical malformation.Due to the proximity of these deformities to the optic chiasm and optic nerves, ocular manifestations are common. Case Report: A 28-year-old male with a long-standing history of reduced vision presented for a routine eye examination. Upon examination he was found to have an afferent pupillary defect, bilateral optic nerve pallor with corresponding nerve fiber layer thinning by optical coherence tomography. Humphrey visual field testing revealed a bi-temporal visual field defect. Neurological imaging was obtained with a subsequent diagnosis of Septo-optic dysplasia (SOD). Conclusion: Our patient had bilateral optic nerve hypoplasia and an absent septum pellucidum without endocrine abnormalities. This case reiterates the importance of accurate diagnosis of amblyopia only in the absence of ocular and neurological disease. This review also highlights the importance of imaging in instances of unexplained optic atrophy.

Optical coherence tomography detects early optic nerve damage before visual field defect in patients with pituitary tumors.

Optical coherence tomography (OCT) is a useful tool for predicting visual recovery after the removal of pituitary tumors. However, the utility of OCT in patients with pituitary tumors and a normal visual field is unclear. We aimed to analyze OCT features in pituitary tumors without visual field defects. Pituitary tumors without visual field defects were selected. A total of 138 eyes from 69 patients, assessed by the Humphrey visual field test and OCT, were enrolled in this study. Using preoperative coronal sections of MR images, patients were divided into chiasmal compression (CC) and non-chiasmal compression (non-CC) groups, and OCT characteristics were examined. The CC and non-CC groups consisted of 40 and 29 patients, respectively. There were no differences in age, sex, tumor type, or degree of visual field testing, but the tumor size was different between the two groups. On OCT, macular thickness ganglion cell complex (mGCC) was significantly thinner in the CC group than that in the non-CC group (112.5 vs 117.4 um, P < 0.05). Based on a database of healthy participants, 24% and 2% of eyes in the CC and non-CC groups had abnormal mGCC thickness (P < 0.01), respectively. In a sub-analysis of the CC group, patients with an abnormal mGCC thickness were older than a normal one (58.2 vs 41.1years, p < 0.01). OCT can detect early optic nerve damage due to optic CC by pituitary tumors, even in normal visual fields. The degree of mGCC thinning may provide an appropriate surgical timing for pituitary tumors that compress the optic chiasm.

Évaluation d’une méthode pupillométrique pour la détection du glaucome

Glaucoma is a progressive optic neuropathy, remaining asymptomatic for a long time, which makes its early diagnosis difficult. Visual field testing is still the gold standard but is less than ideal. The goal of this study is to assess a pupillometric test, administered passively to the subject for one minute, to measure its sensitivity and specificity in the classification of healthy eyes and glaucomatous eyes, and to evaluate its tolerability compared to visual field testing. Forty-five participants were included in this single-center, interventional, prospective study. They underwent 3 monocular pupillometric tests with light stimulation: 6 pupillary responses were recorded during full-field multifocal stimulation (performed twice) and pupillary hippus cycle study. Analysis of spectral power and pupillary measurements with full-field multifocal stimulation provides a 0.94 sensitivity and a 0.88 specificity, a virtually perfect discrimination for early stages of glaucoma. Analysis of pupil cycle time provides a 0.92 sensitivity and a 0.88 specificity for early stages. Acceptability of this test by patients is superior to visual field testing. These results show that data from our pupillometric recordings provide a good classification of healthy and glaucomatous eyes and must be confirmed on a larger population.

Association of Optic Nerve Head and Macular Optical Coherence Tomography Measures With Glaucoma-Related Disability.

Optical coherence tomography (OCT) estimated retinal nerve fiber layer (RNFL) thickness associated with glaucoma-related disability independent of the visual field (VF) damage and thus may provide additional patient-relevant disability information beyond what is captured by standard VF testing. To examine whether OCT metrics [peripapillary RNFL thickness and macular ganglion cell/inner plexiform layer (GCIPL) thickness] are associated with quality of life (QoL) measures and additional disability metrics, and whether these associations are independent of VF damage. In this cross-sectional study, 156 patients with glaucoma or suspected glaucoma received VF testing and OCT scans to measure RNFL and GCIPL thickness. QoL was assessed using the Glaucoma Quality-of-Life 15 and additional disability measures including fear of falling, reading speed, and steps per day were assessed. Multivariable regression models adjusting for relevant covariates tested whether RNFL or GCIPL thickness from the less-impaired eye were associated with disability measures and whether associations were independent of VF damage. Greater VF damage is associated with worse QoL (95% CI=0.4-1.4; P <0.001) and slower reading speed (CI=-0.06 to -0.02; P <0.001). Lower RNFL and GCIPL thicknesses were associated with lower QoL scores, but not with QoL scores or other disability metrics after correcting for VF damage. However, post hoc analyses in patients with better eye thicknesses between 55 and 75µm demonstrated associations between lower RNFL thickness and worse QoL (CI=-2.2 to -0.1; P =0.04) and greater fear of falling (CI=-6.1 to -0.4; P =0.03) even after accounting for VF damage. No such associations were observed for GCIPL thickness. OCT RNFL, but not GCIPL, thickness is associated with multiple disability measures independent of VF damage severity.

Evaluation of the lamina cribrosa in different stages of diabetic retinopathy.

To evaluate the relationship of the peripapillary retina nerve fiber layer (RNFL) and lamina cribrosa (LC) with diabetic retinopathy (DR) in type 2 diabetes mellitus (DM) cases. Prospective comparative study. This study included 50 non-DR (Group 1), 55 non-proliferative diabetic retinopathy (NPDR) (Group 2), 28 DM cases with proliferative diabetic retinopathy (PDR) (Group 3) and 45 healthy volunteers (Group 4). All participants were evaluated with visual acuity, intraocular pressure (IOP) with Goldman applanation tonometry, anterior segment biomicroscopy, 24 - 2 visual field testing, and dilated fundus examination. Retinal nerve fiber layer (RNFL) thickness, lamina cribrosa thickness (LCT) and anterior lamina cribrosa depth (ALCD) were examined by spectral-domain optical coherence tomography (OCT). There was no difference between the groups in terms of age and gender. Visual acuity (p < 0.001) was significantly different between the groups, while IOP (p = 0.068) was similar. Mean (p = 0.010), superior-temporal (p = 0.024), and superior-nasal (p = 0.011) RNFL thickness decreased significantly in correlation with the stage of DR. LCT decreased significantly as the stage of DR progressed in both vertical and horizontal radial OCT scans (p < 0.001). ALCD was not different between groups (p = 0.954 for horizontal scan, p = 0.867 for vertical scan). Peripapillary RNFL and LCT significantly decreases as the DR stage progresses. The biomechanical effects of the LC may also be responsible for diabetes-induced neurodegeneration.

Acute zonal occult outer retinopathy misdiagnosed as giant cell arteritis: a challenging case

Background: Acute zonal occult outer retinopathy (AZOOR) is a rare autoimmune retinopathy that is challenging to diagnose and treat. It usually presents with subtle fundus changes and severe visual symptoms. Herein, we report a challenging case of AZOOR, emphasizing that multimodal imaging could be valuable in diagnosis and monitoring of treatment response.&#x0D; Case Presentation: A 53-year-old woman presented to the emergency department with a one-week history of subacute, severe, painless vision loss without photopsia in her right eye. Her best-corrected distance visual acuity was 20/800 in the right eye and 20/20 in the left eye. Slit-lamp examination findings were unremarkable, and intraocular pressure was normal in both eyes. Initially, fundus examination findings appeared normal; however, serum levels of inflammatory markers were elevated. Brain and orbital magnetic resonance imaging results were unremarkable. A relative afferent pupillary defect was present in subsequent follow-up examinations at the hospital. The patient initially received a diagnosis of posterior ischemic optic neuropathy secondary to occult giant cell arteritis, underwent steroid treatment, and was evaluated by rheumatology and neurology consultants. Both consultants concurred with the presumed diagnosis. Subsequent multimodal imaging in the ophthalmology clinic revealed a trizonal pattern of fundus autofluorescence. Corresponding to these areas, we noted a loss of the ellipsoid zone on optical coherence tomography, depression on multifocal electroretinogram, and scotoma on visual field testing. Accordingly, the diagnosis of AZOOR was made. The patient was referred back to the rheumatologist for initiation of steroid-sparing treatment, and methotrexate was administered. Five months after the initial presentation, the patient showed significant visual field improvement in both eyes.&#x0D; Conclusions: Eye care practitioners should consider AZOOR in the differential diagnosis of patients with subacute painless severe unilateral vision loss and unremarkable findings on fundus examination. Multimodal imaging could be valuable in diagnosis and monitoring of treatment response, as observed in the current case. Further studies with larger sample sizes are needed to confirm the value of multimodal imaging and the available management options for AZOOR.